# Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemoth

Source: https://onco.cc/trials/nct07372079/  
OnCo record `nct07372079` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.

## Summary

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy is a phase 2, interventional study registered as NCT07372079 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 40 participants, started 2026-04-05 and due to reach its primary completion in 2028-12-30. Interventions recorded: QL1706 combined with Chemotherapy. Conditions listed: Breast Cancer; Neoadjuvant Therapy; Immune Checkpoint Inhibitors; QL1706. Triple-negative eligibility wording from the registry: "* Histopathologically confirmed early-stage triple-negative invasive breast cancer as defined by the latest ASCO/CAP guidelines;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07372079
- Phase: 2
- Setting: Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07372079: https://clinicaltrials.gov/study/NCT07372079

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07372079.json